Zimmer Biomet Holdings (ZBH)
Tecnología médica — dispositivos ortopédicos
Zimmer Biomet is one of the big four in global orthopedics (knees, hips, extremities and trauma), with a real moat from patents and clinical switching costs but under pressure from pricing and competition; reported net income carries ~$650 million a year of non-cash intangible amortization from the Biomet merger and the Paragon 28 acquisition, which makes it look more expensive than its owner earnings suggest, while the company raises its 2026 guidance following a strong first half and accelerates its share buyback.
- Price
- $100.13
- Intrinsic value (5y, base)
- $149
- Total annual return (5y)
- 9.0%
- Status (nominal)
- Fairly valued
- Margin of safety
- +19%
The essentials
- Four-player oligopoly in knees, hips and S.E.T. (alongside J&J MedTech, Stryker and Smith & Nephew), with 2026 guidance raised twice during the year after coming in above plan in the first half.
- Reported net income is depressed by ~$650 million a year of non-cash intangible amortization (2015 Biomet merger, 2025 Paragon 28 acquisition) and a $170 million inventory charge in 2025; owner earnings comfortably exceed reported net income.
- Buyback program expanded to up to $1,000 million for 2026, reducing the share count steadily since 2022; the dividend remains flat at $0.96 per share.
Intrinsic value — two valuation methods
Total return at 5 years: 9.1%/year = 8.3% appreciation + 0.8% dividend. The target price ($149) is ex-dividend; the $5 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $194 · Multiples $124) exceeds the market price ($100).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $100 trades ~19.1% below its value discounted to today (~$124); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($149) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$77.
Thesis
The business
Zimmer Biomet is a mid-quality player within a four-firm oligopoly: a real moat via patents, regulatory approval and clinical switching costs, but eroding under pricing pressure (VBP in China, group purchasing organizations, Italy's Pay Back law) and competition from J&J MedTech, Stryker and Smith & Nephew. Return on invested capital, 5.2%, sits below the 10% bar, but that largely reflects the goodwill carried from the Biomet merger (2015) and the Paragon 28 purchase (2025), not a poorly run operation.
The valuation
Valued on P/E over reported net income, with an exit multiple within the med-tech band (16×–22×). The 5-year value comes from projecting revenue anchored to the company's own 2026 guidance (3.9%–4.9% reported) and decelerating toward long-run organic growth, with an entry multiple of 24×. The result is Fairly valued, with an estimated 5-year annual return of +9%.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. The market price is compared against the maximum price that sustains the 15% hurdle, giving a margin of -30%. Reported net income — depressed by ~$650 million a year of non-cash intangible amortization — makes the entry P/E look more expensive than owner earnings (which add that amortization back) suggest.
What to watch
The central disconfirmer is whether the transformation of the U.S. sales force (from independent agents to employees) can be completed without the disruption already suffered during the 2024 ERP transition. If pricing pressure from group purchasing organizations and China's VBP program spreads to more geographies, the adjusted operating margin — currently 26.5% for the half — could compress before the operating leverage implied by the raised guidance materializes.
Educational / informational. Does not constitute investment advice.